Exagen
XGN
About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Employees: 209
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
240% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 5
229% more call options, than puts
Call options by funds: $56K | Put options by funds: $17K
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
184% more capital invested
Capital invested by funds: $22.4M [Q1] → $63.7M (+$41.3M) [Q2]
37% more funds holding
Funds holding: 38 [Q1] → 52 (+14) [Q2]
7.02% more ownership
Funds ownership: 34.84% [Q1] → 41.86% (+7.02%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
B. Riley Securities
Anderson Schock
|
$15
|
Buy
Initiated
|
11 Sep 2025 |
|
Canaccord Genuity
Kyle Mikson
|
$11
|
Buy
Maintained
|
30 Jul 2025 |
|
Keybanc
Paul Knight
|
$12
|
Overweight
Upgraded
|
30 Jul 2025 |
|
Craig-Hallum
John Wilkin
|
$12
|
Buy
Initiated
|
23 Jul 2025 |
Financial journalist opinion
